Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

14.45
+0.16001.12%
Pre-market: 14.39-0.0600-0.42%05:05 EST
Volume:2.91M
Turnover:42.04M
Market Cap:3.73B
PE:4.34
High:14.61
Open:14.45
Low:14.26
Close:14.29
Loading ...

Organon & Co FY2025 Shr View $4.10, REV View $6.47 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
13 Feb

Organon Q4 2024 Adj EPS $0.90 Beats $0.87 Estimate, Sales $1.59B Inline

Benzinga
·
13 Feb

Organon (OGN) Q4 Earnings Report Preview: What To Look For

StockStory
·
12 Feb

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Organon (OGN) and Inventiva (IVA)

TIPRANKS
·
12 Feb

U.S. RESEARCH ROUNDUP-AmEx, Elevance Health, SouthState

Reuters
·
27 Jan

Organon & Co : JP Morgan Cuts Target Price to $18 From $20

THOMSON REUTERS
·
27 Jan

With 79% ownership, Organon & Co. (NYSE:OGN) boasts of strong institutional backing

Simply Wall St.
·
24 Jan

Organon transferred with a Hold at TD Cowen

TIPRANKS
·
15 Jan

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

TipRanks
·
17 Dec 2024

Organon Says Vtama Cream Approved by FDA for Atopic Dermatitis

MT Newswires Live
·
16 Dec 2024

BRIEF-FDA Approves Vtama® Cream, 1% For The Treatment Of Atopic Dermatitis

Reuters
·
16 Dec 2024

FDA Approves Vtama® (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

THOMSON REUTERS
·
16 Dec 2024

BRIEF-FDA Approves Dermavant Science's Vtama For Topical Treatment Of Atopic Dermatitis In Adult & Pediatric Patients 2 Years & Older

Reuters
·
14 Dec 2024

FDA: Approves Dermavant Science's Vtama for Topical Treatment of Atopic Dermatitis in Adult & Pediatric Patients 2 Years & Older - Website

THOMSON REUTERS
·
14 Dec 2024

Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price

Simply Wall St.
·
13 Dec 2024

Merck-marketed asthma drug linked to psychiatric issues: report

seekingalpha
·
22 Nov 2024